Characterization and Management of Cytopenias after Imetelstat Treatment in the IMerge Phase 3 Trial of Patients with Lower-Risk Myelodysplastic Syndromes (LR-MDS)

被引：0
|
作者：
Zeidan, Amer M. [1 ,2 ]
Savona, Michael R. [3 ]
Madanat, Yazan F. [4 ]
Fenaux, Pierre [5 ]
Komrokji, Rami S. [6 ]
Jonasova, Anna [7 ]
Illmer, Thomas
Sun, Libo [8 ]
Berry, Tymara [8 ]
Feller, Faye M. [8 ]
Navada, Shyamala [8 ]
Santini, Valeria [9 ,10 ]
Platzbecker, Uwe [11 ]
机构：
[1] Yale Univ, Yale Sch Med, New Haven, CT USA
[2] Yale Univ, Yale Canc Ctr, New Haven, CT USA
[3] Vanderbilt Univ, Med Ctr, Vanderbilt Ingram Canc Ctr, Nashville, TN USA
[4] UT Southwestern Med Ctr, Harold C Simmons Comprehens Canc Ctr, Dallas, TX USA
[5] Univ Paris 07, Hop St Louis, Paris, France
[6] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA
[7] Gen Hosp, Prague, Czech Republic
[8] Geron Corp, Parsippany, NJ USA
[9] Azienda Osped Univ Careggi, MDS UNIT, DMSC, Florence, Italy
[10] Univ Florence, Florence, Italy
[11] Leipzig Univ Hosp, Cellular Therapy & Hemostaseol, Leipzig, Germany
来源：
BLOOD | 2023年 / 142卷
关键词：
D O I：
10.1182/blood-2023-180962
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：5
相关论文
共 50 条
  • [21] Management of Patients with Lower-Risk Myelodysplastic Neoplasms (MDS)
    Lucero, Josephine
    Al-Harbi, Salman
    Yee, Karen W. L.
    CURRENT ONCOLOGY, 2023, 30 (07) : 6177 - 6196
  • [22] Imetelstat in patients with lower-risk myelodysplastic syndromes who have relapsed or are refractory to erythropoiesis-stimulating agents (IMerge): a multinational, randomised, double-blind, placebocontrolled, phase 3 trial
    Platzbecker, Uwe
    Santini, Valeria
    Fenaux, Pierre
    Sekeres, Mikkael A.
    Savona, Michael R.
    Madanat, Yazan F.
    Diez-Campelo, Maria
    Valcarcel, David
    Illmer, Thomas
    Jonasova, Anna
    Belohlavkova, Petra
    Sherman, Laurie J.
    Berry, Tymara
    Dougherty, Souria
    Shah, Sheetal
    Xia, Qi
    Sun, Libo
    Wan, Ying
    Huang, Fei
    Ikin, Annat
    Navada, Shyamala
    Feller, Faye
    Komrokji, Rami S.
    Zeidan, Amer M.
    LANCET, 2024, 403 (10423): : 249 - 260
  • [23] Relationship of Treatment-Related Cytopenias and Response to Lenalidomide in Patients With Lower-Risk Myelodysplastic Syndromes
    Sekeres, Mikkael A.
    Maciejewski, Jaroslaw P.
    Giagounidis, Aristotle A. N.
    Wride, Kenton
    Knight, Robert
    Raza, Azra
    List, Alan F.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (36) : 5943 - 5949
  • [24] PHASE 1 STUDY EVALUATING LOW-DOSE (LD) ORAL DECITABINE/CEDAZURIDINE (ASTX727) IN LOWER-RISK MYELODYSPLASTIC SYNDROMES (LR-MDS) PATIENTS
    Garcia-Manero, G.
    Bachiashvili, K.
    Amin, H.
    Traer, E.
    Pollyea, D.
    Sallman, D.
    Al-Kali, A.
    Cripe, L.
    Berdeja, J.
    Griffiths, E.
    Mohan, S.
    Vachhani, P.
    Sano, Y.
    Oganesian, A.
    Keer, H.
    Yacoub, A.
    LEUKEMIA RESEARCH, 2023, 128
  • [25] Long-Term Evaluation of Luspatercept in Erythropoiesis-Stimulating Agent (ESA)Intolerant/Refractory Patients (pts) with Lower-Risk Myelodysplastic Syndromes (LR-MDS) in the Phase 3 MEDALIST Study
    Santini, Valeria
    Komrokji, Rami S.
    Garcia-Manero, Guillermo
    Buckstein, Rena
    Oliva, Esther Natalie
    Keeperman, Karen L.
    Rose, Shelonitda
    Giuseppi, Ana Carolina
    Vilmont, Valerie
    Lai, Yinzhi
    Miteva, Dimana
    Aggarwal, Barkha
    Platzbecker, Uwe
    Fenaux, Pierre
    Zeidan, Amer M.
    BLOOD, 2023, 142
  • [26] GDF11/SMAD Regulated Splicing of GATA1 Is Associated with Response to Luspatercept in Lower-Risk Myelodysplastic Syndromes (LR-MDS)
    Aluri, Srinivas
    Fraint, Ellen
    Chakraborty, Samarpana
    Ahsan, Aarif
    Poigailwar, Gowri
    Zhao, Rongbao
    Pradhan, Kith
    Bachiashvili, Kimo
    Budhathoki, Anjali
    Agarwal, Beamon
    Mitchell, Shanisha Gordon
    Carbajal, Milagros
    Sahu, Srabani
    Boultwood, Jacqueline
    Pellagatti, Andrea
    Steidl, Ulrich
    Wickrema, Amittha
    Nandakumar, Satish
    Shastri, Aditi
    Bowman, Teresa
    Vodala, Sadanand
    Verma, Amit K.
    BLOOD, 2023, 142
  • [27] Hematologic and transfusion outcomes in patients (pts) with lower-risk myelodysplastic syndromes (LR-MDS) receiving luspatercept: Real-world assessment in the community practice setting
    Mukherjee, Sudipto
    Brown-Bickerstaff, Cherrishe
    Falkenstein, Angelica
    Makinde, Adeola Y.
    Bland, Emily
    Laney, JaLyna
    Garretson, Marne Prime
    McBride, Ali
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [28] Impact of Luspatercept on Healthcare Resource Use (HCRU) Among Patients with Lower-Risk, Myelodysplastic Syndromes (LR-MDS): A Medical Record Review in Canada, Germany, and Spain
    Diez-Campelo, Maria
    Esterberg, Elizabeth
    Goyal, Ravi K.
    Glassberg, Mrudula B.
    Yucel, Aylin
    Rombi, Julien
    Davis, Keith L.
    Jimenez, Maria
    Miteva, Dimana
    Hnoosh, Ahmed
    Germing, Ulrich
    BLOOD, 2024, 144 : 5055 - 5056
  • [29] Evaluating the Impact of an Electronic Medical Record (EMR) Alert on Appropriate Dosing of Luspatercept in Patients With Lower-Risk Myelodysplastic Syndromes (LR-MDS) in a Community Oncology Network
    Singh, Nisha
    Peters, Brooke
    Chang, Melody
    Maksour, Manale
    McMullen, Nicole
    Winegar, Bradley
    Perkey, Cassandra
    Gavrilov, Svetlana
    Swanson, Ashley
    Slaff, Samantha
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S389 - S390
  • [30] Long Term Responses to Rigosertib in Lower-Risk Myelodysplastic Syndromes (MDS) Patients
    Raza, Azra
    Yalcin, Can
    Cimist, Miray
    Shelton, Ryan
    Bilgrami, Syed Fazl Ali
    Heaney, Mark Lawrence
    Ali, Abdullah Mahmood
    BLOOD, 2017, 130
12345